Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis

Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis

Swiss healthcare company Roche has launched the Elecsys Anti-p53 immunoassay to help in the diagnosis of various types of cancer by the in vitro quantitative determination of anti-p53 antibodies. The Anti-p53 immunoassay test will help physicians in diagnosing oesophageal cancer, breast cancer, and bowel cancer in patients, in combination with other diagnostic tests, said Roche. […]

Pyxis Oncology raises $152m in Series B round for cancer therapies

Pyxis Oncology raises $152m in Series B round for cancer therapies

Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, and other biologics for the treatment of difficult-to-treat cancers. Pyxis Oncology’s Series B round also saw the participation of additional new investors – Perceptive […]

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 billion for the latter’s cancer drug candidate pralsetinib. Through the deal, Roche gains exclusive rights for the co-development and marketing of the investigational drug for RET-altered cancers across the world […]